Efficacy, Safety and Immunogenicity Study of the Recombinant Two-component COVID-19 Vaccine (CHO Cell)(Recov)

NCT05398848 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

7623

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19

Interventions

BIOLOGICAL: Recombinant two-component COVID-19 vaccine (CHO cell)
BIOLOGICAL: Placebo

Sponsor

Jiangsu Rec-Biotechnology Co., Ltd.